J Rhinol.  2020 May;27(1):1-7. 10.18787/jr.2020.00312.

Application of Stem Cell-Derived Extracellular Vesicles in Allergic Airway Diseases

  • 1Department of Otorhinolaryngology-Head and Neck Surgery, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea
  • 2Biomedical Research Institute, Pusan National University Hospital, Busan, Korea


Mesenchymal stem cells (MSCs) have been reported to be promising candidates for the treatment of allergic airway diseases. However, MSCs themselves have several problems including immune rejection, risk of aneuploidy, difficulty of handling, and tumorigenicity. An increasing number of studies demonstrated that administration of conditioned media or extracellular vesicles (EVs) released by MSCs is as effective as the MSCs themselves in suppression of allergic airway inflammation. EVs can exert their effects by delivering their contents such as proteins, mRNAs, and microRNAs to recipient cells. Furthermore, the administration of MSCs-derived EVs may reduce potential safety risks associated with stem cell therapy, suggesting that MSCs-derived EVs may be a promising alternative to cell therapy for allergic airway diseases. This review examines the current understanding of the immunomodulatory properties of MSCs-derived EVs and its therapeutic implication for allergic airway diseases.


Mesenchymal stem cells; Extracellular vesicles; Allergic rhinitis; Asthma; Immunosuppression; 중간엽줄기세포; 세포외 소포체; 알레르기 비염; 천식; 면역 억제
Full Text Links
  • JR
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr